262 related articles for article (PubMed ID: 30567725)
1. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
Roboz GJ; Mandrekar SJ; Desai P; Laumann K; Walker AR; Wang ES; Kolitz JE; Powell BL; Attar EC; Stock W; Bloomfield CD; Kohlschmidt J; Mrózek K; Hassane DC; Garraway L; Jané-Valbuena J; Baltay M; Tracy A; Marcucci G; Stone RM; Larson RA
Blood Adv; 2018 Dec; 2(24):3608-3617. PubMed ID: 30567725
[TBL] [Abstract][Full Text] [Related]
2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
4. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.
Short NJ; Kantarjian HM; Loghavi S; Huang X; Qiao W; Borthakur G; Kadia TM; Daver N; Ohanian M; Dinardo CD; Estrov Z; Kanagal-Shamanna R; Maiti A; Benton CB; Bose P; Alvarado Y; Jabbour E; Kornblau SM; Pemmaraju N; Jain N; Gasior Y; Richie MA; Pierce S; Cortes J; Konopleva M; Garcia-Manero G; Ravandi F
Lancet Haematol; 2019 Jan; 6(1):e29-e37. PubMed ID: 30545576
[TBL] [Abstract][Full Text] [Related]
5. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
Blum W; Sanford BL; Klisovic R; DeAngelo DJ; Uy G; Powell BL; Stock W; Baer MR; Kolitz JE; Wang ES; Hoke E; Mrózek K; Kohlschmidt J; Bloomfield CD; Geyer S; Marcucci G; Stone RM; Larson RA;
Leukemia; 2017 Jan; 31(1):34-39. PubMed ID: 27624549
[TBL] [Abstract][Full Text] [Related]
7. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
Bocchia M; Candoni A; Borlenghi E; Defina M; Filì C; Cattaneo C; Sammartano V; Fanin R; Sciumè M; Sicuranza A; Imbergamo S; Riva M; Fracchiolla N; Latagliata R; Caizzi E; Mazziotta F; Alunni G; Di Bona E; Crugnola M; Rossi M; Consoli U; Fontanelli G; Greco G; Nadali G; Rotondo F; Todisco E; Bigazzi C; Capochiani E; Molteni A; Bernardi M; Fumagalli M; Rondoni M; Scappini B; Ermacora A; Simonetti F; Gottardi M; Lambertenghi Deliliers D; Michieli M; Basilico C; Galeone C; Pelucchi C; Rossi G
Hematol Oncol; 2019 Oct; 37(4):447-455. PubMed ID: 31385337
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Blum W; Schwind S; Tarighat SS; Geyer S; Eisfeld AK; Whitman S; Walker A; Klisovic R; Byrd JC; Santhanam R; Wang H; Curfman JP; Devine SM; Jacob S; Garr C; Kefauver C; Perrotti D; Chan KK; Bloomfield CD; Caligiuri MA; Grever MR; Garzon R; Marcucci G
Blood; 2012 Jun; 119(25):6025-31. PubMed ID: 22566605
[TBL] [Abstract][Full Text] [Related]
9. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
10. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
11. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
12. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
[TBL] [Abstract][Full Text] [Related]
13. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
[TBL] [Abstract][Full Text] [Related]
14. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong VH; Ruppert AS; Mims AS; Borate U; Stein EM; Baer MR; Stock W; Kovacsovics T; Blum W; Arellano ML; Schiller GJ; Olin RL; Foran JM; Litzow MR; Lin TL; Patel PA; Foster MC; Redner RL; Al-Mansour Z; Cogle CR; Swords RT; Collins RH; Vergilio JA; Heerema NA; Rosenberg L; Yocum AO; Marcus S; Chen T; Druggan F; Stefanos M; Gana TJ; Shoben AB; Druker BJ; Burd A; Byrd JC; Levine RL; Boyiadzis MM
Cancer; 2023 Aug; 129(15):2308-2320. PubMed ID: 37078412
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
[TBL] [Abstract][Full Text] [Related]
18. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Blum W; Garzon R; Klisovic RB; Schwind S; Walker A; Geyer S; Liu S; Havelange V; Becker H; Schaaf L; Mickle J; Devine H; Kefauver C; Devine SM; Chan KK; Heerema NA; Bloomfield CD; Grever MR; Byrd JC; Villalona-Calero M; Croce CM; Marcucci G
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7473-8. PubMed ID: 20368434
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Huls G; Chitu DA; Pabst T; Klein SK; Stussi G; Griskevicius L; Valk PJM; Cloos J; van de Loosdrecht AA; Breems D; van Lammeren-Venema D; van Zeventer I; Boersma R; Jongen-Lavrencic M; Fehr M; Hoogendoorn M; Manz MG; Söhne M; van Marwijk Kooy R; Deeren D; van der Poel MWM; Legdeur MC; Tick L; Chalandon Y; Ammatuna E; Blum S; Löwenberg B; Ossenkoppele GJ
Blood Adv; 2020 Sep; 4(18):4267-4277. PubMed ID: 32915972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]